Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)

Inclusion criteria

• Patient is > 18 years of age (or minimum age as required by local regulations).
• The patient has consented to participate and has authorized the collection and release of his medical information by signing the "Patient Informed Consent Form".
• All lesions requiring interventions (target lesions - one to a maximum of four) in one or more native coronary arteries are amendable for implantation of one or more Endeavor® Zotarolimus Eluting Coronary Stent System or Cypher® Sirolimus-eluting Coronary Stent*.
• Patient indication, lesion length and vessel diameter of the target lesion(s) are according to the 'Indications for Use' as mentioned in the 'Instructions for Use' that comes with every Endeavor® Zotarolimus Eluting Coronary Stent System and Cypher® Sirolimus-eluting Coronary Stent. Patients should qualify for both systems before randomization*.
• The patient is willing and able to cooperate with study procedures and required follow up visits.

Exclusion criteria

• Women with known pregnancy or who are lactating.
• Planned elective surgery necessitating discontinuation of clopidogrel within the regular planned period of clopidogrel administration.
• Patients expected not to be compliant with the anti-platelet and/or anticoagulation therapy regimen.
• Previous brachy-therapy.
• Previous implantation of a drug eluting stent.
• Previous implantation of a bare metal stent in the preceding year.
• Simultaneous or planned intervention other non cardiac vessels including but not limited to renal artery or carotid artery.
• Current medical condition with a life expectancy of less than 3 years.
• Manifest acute severe heart failure (Killip class III-IV).
• The patient is currently, and during the first 3 years of the PROTECT trial, participating in another investigational device or drug study that clinically interferes with the PROTECT-study endpoints; or requires coronary angiography or other coronary artery imaging procedures. The patient may only be enrolled in the PROTECT-study once.
• Patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this study.
• Patients on warfarin or similar anti-coagulant therapy.
• Patients with hypersensitivity or allergies to one of the drugs or components indicated in the Instructions for Use of either stents.
• Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.
• Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated.
• Transplant patients.